Read by QxMD icon Read

Pediatric Blood & Cancer

Rahel Kasteler, Linda M H Kam, Annette Weiss, Nicolas Waespe, Grit Sommer, Florian Singer, Nicolas X von der Weid, Marc Ansari, Claudia E Kuehni
BACKGROUND: Childhood cancer survivors are at increased risk for pulmonary morbidity and mortality. International guidelines recommend pulmonary function tests (PFT) during follow-up care. This nationwide study assessed how many children received PFT within 5 years after pulmotoxic treatment in Switzerland, types of tests, and predictors for testing. METHODS: We included all children from the Swiss Childhood Cancer Registry who were diagnosed with cancer from 1990 to 2013 at age 0-16 years, survived for ≥2 years from diagnosis, and had pulmotoxic chemotherapy with bleomycin, busulfan, nitrosoureas, and/or chest radiotherapy...
June 15, 2018: Pediatric Blood & Cancer
Dimitrios A Savva, Nicole Herrera, Radha Rohatgi
BACKGROUND: The American Society of Clinical Oncology guidelines recommend rasburicase for the treatment of pediatric patients with hyperuricemia at risk of tumor lysis syndrome (TLS) using a weight-based dose of 0.1-0.2 mg/kg once daily for 1-7 days. However, there has been a trend in practice due to recent data showing benefit using a fixed-dose approach. The purpose of this study was to evaluate the efficacy and safety between fixed and weight-based dosing of rasburicase in a pediatric population...
June 15, 2018: Pediatric Blood & Cancer
Sarah L Reeves, Hannah K Jary, Jennifer P Gondhi, Mary Kleyn, Abram L Wagner, Kevin J Dombkowski
BACKGROUND: Children with sickle cell anemia and sickle cell trait are at an increased risk of invasive pneumococcal disease compared to children with normal hemoglobin. We assessed and compared pneumococcal vaccination status among these three groups. PROCEDURE: Children with sickle cell anemia and sickle cell trait were identified using Michigan newborn screening records (1997-2014); each child was matched to four children with normal hemoglobin based on age, Medicaid enrollment (at least 1 year from 2012-2014), race, and census tract...
June 15, 2018: Pediatric Blood & Cancer
Rebecca Epperly, John Ozolek, Kyle Soltys, Debra Cohen, Rakesh Goyal, Erika Friehling
Post-transplant lymphoproliferative disorder (PTLD) related plasma cell neoplasms are rare in pediatric patients. We report a pediatric liver transplant recipient with plasma cell myeloma type PTLD. Cytogenetics included 1q duplication, associated with poor prognosis in adult multiple myeloma, and t(8;14). High-risk cytogenetics has not been reported in pediatric plasma cell myeloma type PTLD. The patient was treated with bortezomib, dexamethasone, and lenalidomide with subsequent autologous stem cell transplant...
June 12, 2018: Pediatric Blood & Cancer
Lubaina Ehsan, Mariam Rashid, Najveen Alvi, Khadija Awais, Omair Nadeem, Aleezay Asghar, Fatimah Sajjad, Malika Fatima, Asim Qidwai, Shabneez Hussain, Erum Hasan, Nick Brown, Sadaf Altaf, Babar Hasan, Salman Kirmani
BACKGROUND: Endocrinopathy due to iron overload is the most common morbidity whereas myocardial siderosis causing toxic cardiomyopathy is the leading cause of mortality among patients with transfusion dependent thalassemia major (TDTM). If detected early, this can be treated with aggressive chelation. T2* cardiac magnetic resonance imaging (CMR) guided chelation protocols are now the gold standard but have limited availability in low and middle-income countries. We hypothesized that markers of endocrine dysfunction would correlate with T2* CMR and can be used to predict the severity of myocardial siderosis and guide chelation therapy...
June 12, 2018: Pediatric Blood & Cancer
Lindsay A Jibb, Kathryn A Birnie, Paul C Nathan, Tanya N Beran, Vanessa Hum, J Charles Victor, Jennifer N Stinson
BACKGROUND: Subcutaneous port needle insertions are painful and distressing for children with cancer. The interactive MEDiPORT robot has been programmed to implement psychological strategies to decrease pain and distress during this procedure. This study assessed the feasibility of a future MEDiPORT trial. The secondary aim was to determine the preliminary effectiveness of MEDiPORT in reducing child pain and distress during subcutaneous port accesses. METHODS: This 5-month pilot randomized controlled trial used a web-based service to randomize 4- to 9-year-olds with cancer to the MEDiPORT cognitive-behavioral arm (robot using evidence-based cognitive-behavioral interventions) or active distraction arm (robot dancing and singing) while a nurse conducted a needle insertion...
June 12, 2018: Pediatric Blood & Cancer
Maya Prasad, Gaurav Narula, Girish Chinnaswamy, Brijesh Arora, Tanuja Shet, Poonam Panjwani, Manju Sengar, Siddharth Laskar, Nehal Khanna, Shripad Banavali
BACKGROUND: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is an uncommon subtype of Hodgkin lymphoma (HL) with few published studies in children, entirely from North America and Europe. We analyzed clinical features and treatment outcome of pediatric NLPHL. PROCEDURE: Children less than 18 years of age diagnosed after histopathology review to have NLPHL between June 1998 and August 2016 were retrospectively analyzed. Descriptive details of clinical presentation and treatment were collected, and outcomes analyzed using Kaplan-Meier survival analysis...
June 12, 2018: Pediatric Blood & Cancer
Akihiro Tamura, Toshiaki Ishida, Atsuro Saito, Nobuyuki Yamamoto, Takehito Yokoi, Suguru Uemura, Nanako Nino, Takahiro Fujiwara, Teppei Tahara, Sayaka Nakamura, Aiko Kozaki, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka
The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics...
June 12, 2018: Pediatric Blood & Cancer
Hadeel Halalsheh, Mary Beth McCarville, Michael Neel, Mark Reynolds, Michael C Cox, Alberto S Pappo
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
June 12, 2018: Pediatric Blood & Cancer
Lisa Pahl, Rita Beier, Nils von Neuhoff, Bernd Auber, Michaela Höfs, Eva-Christina Prott, Brigitte Schlegelberger, Dirk Reinhardt, Doris Steinemann
No abstract text is available yet for this article.
June 12, 2018: Pediatric Blood & Cancer
Ye Jee Shim, So Yun Park, Nani Jung, Heung Sik Kim, Jung-Sook Ha, Ja-Hyun Jang
A 10-year-old male and his family members visited a pediatric hematology clinic due to coagulopathy. Laboratory tests indicated von Willebrand disease (vWD) in all the family members. We conducted diagnostic exome sequencing for confirmation. The patient was confirmed to be a compound heterozygote for vWD: c.2574C > G (p.Cys858Trp) from his father (known variant of vWD type 1) and c.3390C > T (p.Pro1127_Gly1180delinsArg) from his mother (variant known to result in exon 26 skipping in vWD type 2A)...
June 12, 2018: Pediatric Blood & Cancer
Hyoung Jin Kang, Susan Loftus, Cara DiCristina, Stuart Green, Annpey Pong, Christian Michel Zwaan
BACKGROUND: This was a subgroup analysis of age group, dexamethasone use, and very highly emetogenic chemotherapy (VHEC) use from a randomised, multicentre, double-blind, Phase 3 study of oral aprepitant in paediatric subjects. METHODS: Subjects aged 6 months to 17 years scheduled to receive chemotherapeutic agents associated with at least moderate risk for emesis were randomly assigned to receive either aprepitant plus ondansetron (aprepitant regimen) or placebo plus ondansetron (control regimen); both could be administered with or without dexamethasone...
June 12, 2018: Pediatric Blood & Cancer
Uma H Athale, Maneka Puligandla, Kristen E Stevenson, Barbara Asselin, Luis A Clavell, Peter D Cole, Kara M Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A Schorin, Maria Luisa Sulis, Jennifer J G Welch, Marian H Harris, Donna S Neuberg, Stephen E Sallan, Lewis B Silverman
BACKGROUND: Children and adolescents with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) are reported to have increased relapse rates and therapy-related mortality (TRM). Treatment regimens for DS-ALL patients often include therapy modifications. Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols have used same risk-stratified treatment for patients with and without DS. PROCEDURES: We compared clinical and outcome data of DS (n = 38) and non-DS (n = 1,248) patients enrolled on two consecutive DFCI ALL trials 00-001 (2000-2004) and 05-001 (2005-2011) with similar risk adapted therapy regardless of DS status...
June 7, 2018: Pediatric Blood & Cancer
Nancy A Kernan, Paul G Richardson, Angela R Smith, Brandon M Triplett, Joseph H Antin, Leslie Lehmann, Yoav Messinger, Wei Liang, Robin Hume, William Tappe, Robert J Soiffer, Stephan A Grupp
BACKGROUND: Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially fatal complication of conditioning for hematopoietic stem cell transplantation (HSCT) but can occur after nontransplant-associated chemotherapy. Following HSCT, VOD/SOS with multi-organ dysfunction (MOD) may be associated with >80% mortality. Defibrotide is approved to treat severe hepatic VOD/SOS post-HSCT in patients aged >1 month in the European Union and hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the United States...
June 6, 2018: Pediatric Blood & Cancer
Christopher Weldon
No abstract text is available yet for this article.
June 6, 2018: Pediatric Blood & Cancer
Ugonna T Offor, Ralph K Akyea, Janet E Neequaye, Lorna A Renner, Catherine I Segbefia
BACKGROUND: Burkitt lymphoma (BL) is the most common childhood cancer in Ghana, where the endemic variant is the predominant subtype and historically presents as a highly chemo-sensitive jaw tumor. This study aimed to update the current epidemiological characteristics of childhood BL in our institution. PROCEDURE: Patient data for all children diagnosed with BL and seen at Korle Bu Teaching Hospital between January 2007 and December 2012 were retrospectively analyzed...
June 6, 2018: Pediatric Blood & Cancer
H M Agha, A F AbdelMassih, M Y AbdelRahman, O Milanesi, B Castaldi, G Geranio, M C Putti, A Kharabish, R Esmail, G El-Kamah, M Hamdy, H El-Baz, N El-Behary, C Hanna, H El-Tagy, M A Mishriky, M Mamdouh, A Livio, T Ramadan
The relationship between myocardial iron load and eccentric myocardial remodeling remains an under-investigated area; it was thought that remodeling is rather linked to fibrosis. This study aims to determine whether or not measures of remodeling can be used as predictors of myocardial iron. For this purpose, 60 patients with thalassemia were studied with 3D echocardiography and myocardial relaxometry (T2*) by Cardiac MRI. 3D derived sphericity index was significantly higher in patients with myocardial iron load...
June 6, 2018: Pediatric Blood & Cancer
Yu-Hua Chao, Chiao-Wen Lin, Hui-Hsien Pan, Shun-Fa Yang, Te-Fu Weng, Ching-Tien Peng, Kang-Hsi Wu
BACKGROUND: Although immune-mediated pathogenesis is considered an important aspect of severe aplastic anemia (SAA), its underlying mechanisms remain unclear. Mesenchymal stem cells (MSCs) are essential to the formation of specialized microenvironments in the bone marrow (BM), and MSC insufficiency can trigger the development of SAA. METHODS: To find MSC alterations in the SAA BM, we compared BM MSCs from five children with SAA and five controls. Peripheral blood mononuclear cells (PBMCs) were cocultured with MSCs to evaluate the supportive effects of MSCs on hematopoiesis...
June 5, 2018: Pediatric Blood & Cancer
Sudeep Saxena, Hwan Ing Hee
No abstract text is available yet for this article.
June 5, 2018: Pediatric Blood & Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"